Bei Y, He J, Dong X, Wang Y, et al. Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma. Cancer Res 2023 May 19:CAN-23-0510. doi: 10.1158/0008-5472.CAN-23-0510.
PMID: 37205633